RE:RE:Only In Canada you say !An
extremely important development considering the prevalence of anti-viral drug resistance!
Oden6570 wrote: Importantly, the lipid-targeting TLD-1433 PDT as a virus inactivation strategy is not susceptible to provoking evolution of viral resistance to antiviral treatment. The envelope is not encoded by the viral genome and is not produced during intracellular virus replication, but is inherited from the host cell. This circumstance is especially important for the population of immunocompromised patients, who have ongoing viral replication and prolonged anti-viral drug exposure. The latter presents an increasing concern of selection of strains resistant to further treatment. Hence, TLD-1433 PDT, as a novel ROS-dependent virus inactivation strategy, could be a putative alternative to current agents such as formalin for the preparation of inactivated vaccines. As mentioned above, the inactivation of coronavirus by TLD1433 PDT-induced ROS did not affect the availability of viral surface proteins responsible for immune recognition.